Skip to main content
. 2021 Nov 4;10(11):3008. doi: 10.3390/cells10113008

Figure 7.

Figure 7

Effect of inhibitor targeting PI3K/Akt, MAPK/Erk, ERα, and LRP6 pathways on FGFR1 overexpression-induced signal transduction. PI3K/Akt targeting LY294002, MAPK/Erk targeting PD98059 and ER targeting fulvestrant/ICI 182,780 (ICI) were used for the tests. MCF-7/C and MCF-7/FGFR1 cells were treated with palbociclib (0, 5 μM) and each specific inhibitor alone or in combination for 24 h, followed by Western blot analysis of specified markers. (A) The paired cell lines were treated with palbociclib and/or LY294002 (20 μM); (B) the paired cell lines were treated with palbociclib and/or PD98059 (20 μM); (C) the paired cell lines were treated with palbociclib and/or ICI (100 nM). Each panel was probed with the target of the specific inhibitor and other key markers of RTK, ER, and LRP6 signaling.